A concise review of the cost-effectiveness of coronary heart disease prevention (Q33843673)

29 July 2017

1 reference

title

A concise review of the cost-effectiveness of coronary heart disease prevention (English)

1 reference

29 July 2017

main subject

coronary artery disease

1 reference

Brown AI

1

1 reference

29 July 2017

Garber AM

series ordinal

2

1 reference

29 July 2017

publication date

1 January 2000

1 reference

Medical Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

84

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

279-97, xi

1 reference

Cost-effectiveness of cardiac rehabilitation after myocardial infarction.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

The cost-effectiveness of three smoking cessation programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Lowering risk without lowering cholesterol: implications for national cholesterol policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

A cost effective, community based heart health promotion project in England: prospective comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of educational interventions to improve patient outcomes in blood pressure control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

HRT: an analysis of benefits, risks and costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost effectiveness in the detection of renal artery stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Strategies for reducing coronary risk factors in primary care: which is most cost effective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Case mix, costs, and outcomes. Differences between faculty and community services in a university hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Costs and health consequences of cholesterol screening for asymptomatic older Americans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness perspectives in coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cholesterol reduction yields clinical benefit. A new look at old data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Hormone therapy to prevent disease and prolong life in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

A cost-effectiveness analysis of exercise as a health promotion activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of a smoking cessation program after myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness analysis in heart disease, Part I: General principles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Screening for hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Measures of clinical efficacy. Cost-effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Economics of a reduction in smoking: case study from Heartbeat Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Direct medical costs of coronary artery disease in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Physician extenders for cost-effective management of hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Health spending, delivery, and outcomes in OECD countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness in clinical cardiology. II. Preventive strategles and arrhythmla therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

The evidence base for the cost effectiveness of cardiac rehabilitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Hormone replacement therapy: benefit, risk and cost considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

12 Cost-effectiveness of hormone replacement therapy after the menopause

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Impact and cost-effectiveness of smoking interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of interventions to prevent or treat coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness of hormone replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Geographic variation in expenditures for physicians' services in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

Cost-effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970219-4

10.1016/S0025-7125(05)70219-4

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference